Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 215Rectal Neoplasms 85Colonic Neoplasms 76Stomach Neoplasms 56Pancreatic Neoplasms 44Neoplasm Metastasis 40Esophageal Neoplasms 37Neoplasms 28Lung Neoplasms 27Carcinoma, Non-Small-Cell Lung 20Small Cell Lung Carcinoma 19Adenocarcinoma Of Esophagus 19Glioblastoma 18Glioma 17Neuroblastoma 16Esophageal Squamous Cell Carcinoma 16Brain Neoplasms 16Breast Neoplasms 15Sarcoma 11Gliosarcoma 10Biliary Tract Neoplasms 10Central Nervous System Neoplasms 9Astrocytoma 8Adenocarcinoma 8Oligodendroglioma 7Medulloblastoma 7Colorectal Cancer Metastatic 7Rhabdomyosarcoma 6Recurrence 6Locally Advanced Rectal Cancer 6

Interventions

anlotinib 1S 1 (combination) 1Oxaliplatin 1Irinotecan 1Immune Checkpoint Inhibitors 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Overall Survival × Irinotecan × Clear all
NCT03726021 2023-03-29

Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer

Qingdao Central Hospital

Phase 2 Completed
47 enrolled

Overall Survival

Data powered by HemOnc (CC BY 4.0) Colophon âš¡